Bessemer Group
ARQT icon

Bessemer Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Bessemer Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5K Hold
190
– – ﹤0.01% 2263
2026
Q1 		$4K Buy
190
+52
+38% +$1.33K ﹤0.01% 2249
2025
Q4 		$4K Hold
138
– – ﹤0.01% 2276
2025
Q3 		$3K Buy
+138
New +$2.18K ﹤0.01% 2219
2024
Q4 		– Sell
-110
Closed -$1K – 2456
2024
Q3 		$1K Sell
110
-250
-69% -$2.47K ﹤0.01% 2327
2024
Q2 		$3K Buy
+360
New +$3.26K ﹤0.01% 1808

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bessemer Group's ARQT Position: Q2 2026 in Review

Bessemer Group held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 190 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #2263.

Bessemer Group first reported a position in ARQT in Q2 2024 and has held it in 6 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Bessemer Group held 190 shares of Arcutis Biotherapeutics worth $5K as of Q2 2026.
  • Bessemer Group left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2263 holding.
  • Bessemer Group first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 6 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.